BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, December 7, 2025
See today's BioWorld
See today's BioWorld MedTech
Home
» India’s restriction on API exports gives rise to more calls for U.S. drug, device manufacturing
To read the full article
sign up for free
or
sign in
.
India’s restriction on API exports gives rise to more calls for U.S. drug, device manufacturing
March 3, 2020
By
Mari Serebrov
Against the backdrop of the global spread of COVID-19, India announced restrictions Tuesday on the export of 26 active pharmaceutical ingredients (APIs) and formulations of those ingredients.
BioWorld
BioWorld MedTech
Drugs
Medical devices and technologies
Regulatory
Coronavirus
Vaccine
Asia-Pacific
U.S.